Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients

Anti-GD2 strategy in the treatment of neuroblastoma

(2014) R.K. Yang et al.   DRUGS OF THE FUTURE

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response

(2013) Holger N. Lode et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

(2011) Thorsten Simon et al.   BMC CANCER

Dose Finding Study for the Use of Subcutaneous Recombinant Interleukin-2 to Augment Natural Killer Cell Numbers in an Outpatient Setting for Stage 4 Neuroblastoma After Megatherapy and Autologous Stem-Cell Reinfusion

(2010) Ruth Ladenstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acidN-glycolylneuraminic acid

(2010) Rachel E. Taylor et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia

(2010) Linda S. Sorkin et al.   PAIN